

## ASX ANNOUNCEMENT

10 October 2022

### Board Changes

---

IDT Australia Limited (ASX: IDT) (**the Company**) is pleased to advise that Mr Mark Simari and Mr Geoffrey Sam, OAM have been appointed as independent Non-executive Directors of the Company, effective today. The Company also advises that Mr Hugh Burrill will retire as Director of the Company, effective today, and Mr Michael Kotsanis has advised the Board of his intention to retire at the conclusion of the 2022 Annual General Meeting.

Mark Simari is an experienced and accomplished professional in the health care industry and has over 15 years' Board experience in a diverse range of organisations. Mark is currently Chairman of Careteq Limited (ASX:CTQ), Tali Digital Limited (ASX: TD1) and was the co-Founder of Paragon Care (ASX:PGC) and Managing Director from 2008 to 2018 and recently Non-executive Director from 2019 to 2022.

Geoffrey Sam, OAM is currently the Chairperson and independent Non-executive Director of Earlypay Ltd (ASX:EPY) and independent Non-executive Director of Paragon Care Ltd (ASX:PGC). He has also held previous independent Non-executive Board positions with listed companies Money 3 Ltd, Hutchinsons Childcare Services Ltd and was Managing Director of Nova Health Ltd. He is the Co-Founder and Board member of Healthe Care Australia Pty Ltd, a privately owned health care company comprising a portfolio of 18 hospitals.

Geoffrey holds a Bachelor of Commerce (Accounting and Finance) from UNSW, a Master of Health Administration from UNSW, a Master of Arts (Economics and Social Studies) from the University of Manchester UK and is a Fellow of the Australian Institute of Company Directors.

The Board wishes to thank Mr Burrill and Mr Kotsanis for their significant contributions and dedication to the Company during their tenures as Non-executive Directors.

Ends..../

## **IDT**

Authorised by the Board of Directors of IDT Australia Limited.

### **About IDT**

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.